Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy

Breast Cancer

Volumn 21, Issue 4, 2014, Pages 387-393

  Lee, Hyun Jung ^a   Kim, Dae Young ^b   Keam, Bhumsuk ^a   Lee, Jeong Hoon ^a   Han, Sae Won ^a   Oh, Do Youn ^a   Yoon, Jung Hwan ^a   Kim, Tae You ^a   Kim, Yu Jung ^c   Lee, Keun Wook ^c   Kim, Jin Wook ^c   Jeong, Sook Hyang ^c   Lee, Jong Seok ^c   Kim, Jee Hyun ^c   Im, Seock Ah ^a  

^a Seoul National University Hospital   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Breast cancer; Hepatitis B virus; Lamivudine; Reactivation

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; METHOTREXATE; PACLITAXEL; VIRUS DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; LIVER FUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR INVASION; VIRUS CARRIER; VIRUS REACTIVATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST NEOPLASMS; FOLLOW UP; GENETICS; ISOLATION AND PURIFICATION; LIVER FUNCTION TEST; METABOLISM; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PREMEDICATION; PROGNOSIS; PROSPECTIVE STUDY; VIROLOGY; VIRUS ACTIVATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIVER FUNCTION TESTS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PREMEDICATION; PROGNOSIS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS ACTIVATION;

EID: 84904749130     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-012-0417-3     Document Type: Article

References (22)

1. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100(1):182-8.
2. Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol. 1997;8(suppl 1):S107.
3. Liang R, Lau GKK, Kwong Y. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol. 1999;17(1):394.
4. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62(3):299-307.
5. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004;90(7):1306-11. (Pubitemid 38586252)
6. Cheng AL. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma. Blood. 1996;87(3):1202.
7. NCI. Cancer incidence in 2008. Available from: http://www.cancer.go.kr/ cms/statics/incidence/index.html (2010).
8. Jeong S, Yim HW, Bae SH, Lee W. Changes of hepatitis B surface antigen seroprevalence in Korea, 1998-2005. Korean J Epidemiol. 2008;30(1):119-27.
9. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148(7):519-28. (Pubitemid 351665421)
10. Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2006;24(7):1003-16. (Pubitemid 44386525)
11. Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2004;88(3):209-15. (Pubitemid 40137299)
12. Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int. 2004;24(6):540-6. (Pubitemid 40028604)
13. Yun J, Kim K, Kang E, Gwak G, Choi M, Lee J, et al. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer. 2011;104(4):559-63.
14. Lee KS, Kim DJ. Management of chronic hepatitis B. Korean J Hepatol. 2007;13(4):447-88.
15. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat. 2008;15(2):89-102.
16. Gauthier J, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis. 1999;180(6):1757-62.
17. Keam B, Lee JH, Im SA, Yoon JH. Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy. J Natl Compr Canc Netw. 2011;9(5):465-77.
18. Pelizzari AM, Motta M, Cariani E, Turconi P, Borlenghi E, Rossi G. Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol J. 2004;5(4):325-8. (Pubitemid 39214210)
19. Lee YC, Young KC, Su WC, Tsao CJ, Chen TY. Emergence of YMDD mutant hepatitis B virus after allogeneic stem cell transplantation from a HBsAG-positive donor during lamivudine prophylaxis. Haematologica. 2004;89(4):ECR09.
20. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682-95. (Pubitemid 41007823)
21. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125(6):1742-9. (Pubitemid 37500439)
22. Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int. 2008;2(2):152-62. (Pubitemid 351650143)